Global Next Generation Cancer Diagnostics Market 2013-2017 and 2025 By Technology (NGS, LOAC and RT-PCR), Application (CTC, Biomarker), By Cancer Type (Lung, Breast) and Function Companion Diagnostics - Research and Markets

DUBLIN, April 20, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Next Generation Cancer Diagnostics Market Size & Forecasts By Technology (NGS, LOAC & RT-PCR), By Application (CTC, Biomarker), By Cancer Type (Lung, Breast), By Function Companion Diagnostics), And Trend Analysis, 2013 - 2024" report to their offering.

The global next generation cancer diagnostics market is anticipated to reach USD 11.04 billion by 2024

Key drivers for this vertical include rising advancement in genomics and proteomics-based research coupled with increasing prevalence of oncology disorders.

Rise in number of oncological research projects to elucidate tumorigenesis and the underlying mechanisms, consequently raising the demand for serial sampling, diagnosis, and therapeutic manipulation, is a growth rendering driver of this market.

Further Key Findings from the Study Suggest:

• The qPCR & multiplexing segment captured the largest market share in 2015 owing to the presence of a wide product portfolio serving numerous applications in oncology R&D
• Next generation sequencing services and solutions for oncology applications are anticipated to be the fastest growing segment
• Oncology diagnostics in biomarker discovery is expected witness growth as it subsequently facilitates drug designing and identification of novel targets against tumors
• On the basis of cancer type, this vertical is segmented into lung, breast, colorectal, cervical, and other forms of cancer
• Research projects to establish the therapeutic index of anticancer cytotoxic drugs are one of the key factors responsible for expected growth
• North America dominated the market with respect to revenue generation in 2014 due to concerted efforts directed toward the development of next generation sequencing technology and companion diagnostics in personalized medicine
• Some of the key players contributing significantly to the next generation cancer diagnostics market are Novartis AG; Cepheid; Hoffman La Roche Ltd.; PerkinElmer, Inc.; Sysmex Corporation; Abbott; Thermo Fisher Scientific, Inc.; Koninklijke Philips N.V.; Agilent Technologies; Illumina, Inc.; Genomic Health, Inc.; Qiagen; Janssen Global Services, LLC; Hologic, Inc.; Myriad Genetics, Inc.; Almac Group; Opko Health, Inc.; and GE Healthcare.

Key Topics Covered:

1 Executive Summary

2 Next Generation Cancer Diagnostics Industry Outlook
2.1 Market segmentation
2.2 Market size and growth prospects, 2013 - 2024
2.3 Next generation cancer diagnostics market dynamics
2.3.1 Market driver analysis
2.3.1.1 Exponentially decreasing cost of genetic sequencing
2.3.1.2 Development of cluster chip technology and potential applications of CTC in cancer management
2.3.1.3 Rising demand for preventive medicine & companion diagnostics
2.3.1.4 Growing cancer incidence
2.3.2 Market restraint analysis
2.3.2.1 Requirement of expensive laboratory set-up for implementation of novel tests
2.4 Key Opportunities Prioritized
2.5 Industry analysis - Porter's
2.6 Next Generation Cancer Diagnostics PESTEL Analysis

3 Next Generation Cancer Diagnostics Technology Outlook
3.1 Global next generation cancer diagnostics revenue share, by technology, 2015 & 2024
3.2 NGS-based cancer diagnostics
3.3 qPCR & Multiplexing
3.4 Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
3.5 Protein microarrays-based cancer diagnostics
3.6 DNA microarrays-based cancer diagnostics

4 Next Generation Cancer Diagnostics Outlook by Cancer Type
4.1 Global next generation cancer diagnostics revenue share, by cancer type, 2015&2024
4.2 Lung cancer
4.3 Breast cancer
4.4 Colorectal cancer
4.5 Cervical cancer
4.6 Other types of cancer

5 Next Generation Cancer Diagnostics Outlook by Application Outlook
5.1 Global next generation cancer diagnostics revenue share, by application, 2015&2024
5.2 Biomarker development
5.3 CTC analysis
5.4 Proteomic analysis
5.5 Epigenetic analysis
5.6 Genetic analysis

6 Next Generation Cancer Diagnostics Outlook by Function
6.1 Global next generation cancer diagnostics revenue share, by function, 2015&2024
6.2 Therapeutic monitoring
6.3 Companion diagnostics
6.4 Prognostic diagnostics
6.5 Cancer screening
6.6 Risk analysis

7 Next Generation Cancer Diagnostics Regional Outlook

8 Competitive Landscape

For more information about this report visit http://www.researchandmarkets.com/research/f6rck6/next_generation

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com